GAL and lung cancer: Interestingly, Gal-3 is also reportedly increased in lung cancer, and monocytic MDSC with Gal-3 may induce cellular resistance to chemotherapy treatment [51], confirming that posttranslational modification of Gal affects subcellular location and functionality.